Glomerulonephritis Treatment Market Report

Global and Region Glomerulonephritis Treatment Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 03, 2022
  • PAGES：195
  • REPORT CODE：GMM1009821
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Glomerulonephritis Treatment market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Glomerulonephritis Treatmentmarket, defines the market attractiveness level of Glomerulonephritis Treatment market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Glomerulonephritis Treatment industry, describes the types of Glomerulonephritis Treatment market, the applications of major players and the market size, and deeply analyzes the current situation of the global Glomerulonephritis Treatment market and the development prospects and opportunities of Glomerulonephritis Treatment industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Glomerulonephritis Treatment market in Chapter 13.

    By Player:

    • Cellmid Ltd

    • Achillion Pharmaceuticals Inc

    • Shire Plc

    • Merck KGaA

    • Anthera Pharmaceuticals Inc

    • Pfizer Inc

    • Ra Pharmaceuticals Inc

    • Retrophin Inc

    • Biogen Inc

    • Dimerix Bioscience Pty Ltd

    • GlaxoSmithKline Plc

    • Visterra Inc

    • Rigel Pharmaceuticals Inc

    • Bristol-Myers Squibb Company

    • ChemoCentryx Inc

    • Omeros Corp

    • Complexa Inc

    • Pharmalink AB

    By Type:

    • ACH-5228

    • AMY-101

    • Atacicept

    • Avacopan

    • AVX-002

    By End-User:

    • Home Care

    • Clinic

    • Hospital

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Glomerulonephritis Treatment Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Glomerulonephritis Treatment Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Glomerulonephritis Treatment Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Glomerulonephritis Treatment Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Glomerulonephritis Treatment Market Analysis and Outlook to 2022

    • 7.1 Global Glomerulonephritis Treatment Consumption (2017-2022)

    • 7.2 United States Glomerulonephritis Treatment Consumption (2017-2022)

    • 7.3 Europe Glomerulonephritis Treatment Consumption (2017-2022)

    • 7.4 China Glomerulonephritis Treatment Consumption (2017-2022)

    • 7.5 Japan Glomerulonephritis Treatment Consumption (2017-2022)

    • 7.6 India Glomerulonephritis Treatment Consumption (2017-2022)

    • 7.7 South Korea Glomerulonephritis Treatment Consumption (2017-2022)

    8 Region and Country-wise Glomerulonephritis Treatment Market Analysis and Outlook to 2028

    • 8.1 Global Glomerulonephritis Treatment Consumption Forecast (2022-2028)

    • 8.2 United States Glomerulonephritis Treatment Consumption Forecast (2022-2028)

    • 8.3 Europe Glomerulonephritis Treatment Consumption Forecast (2022-2028)

    • 8.4 China Glomerulonephritis Treatment Consumption Forecast (2022-2028)

    • 8.5 Japan Glomerulonephritis Treatment Consumption Forecast (2022-2028)

    • 8.6 India Glomerulonephritis Treatment Consumption Forecast (2022-2028)

    • 8.7 South Korea Glomerulonephritis Treatment Consumption Forecast (2022-2028)

    9 Global Glomerulonephritis Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Glomerulonephritis Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global ACH-5228 Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global AMY-101 Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Atacicept Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Avacopan Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global AVX-002 Consumption and Growth Rate (2017-2022)

    • 9.2 Global Glomerulonephritis Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Home Care Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Hospital Consumption and Growth Rate (2017-2022)

    10 Global Glomerulonephritis Treatment Market Outlook by Types and Applications to 2028

    • 10.1 Global Glomerulonephritis Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global ACH-5228 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global AMY-101 Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Atacicept Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Avacopan Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global AVX-002 Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Glomerulonephritis Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Home Care Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    11 Global Glomerulonephritis Treatment Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Glomerulonephritis Treatment Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Glomerulonephritis Treatment Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Glomerulonephritis Treatment Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Glomerulonephritis Treatment Market Competitive Analysis

    • 14.1 Cellmid Ltd

      • 14.1.1 Cellmid Ltd Company Details

      • 14.1.2 Cellmid Ltd Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Cellmid Ltd Glomerulonephritis Treatment Product and Service

    • 14.2 Achillion Pharmaceuticals Inc

      • 14.2.1 Achillion Pharmaceuticals Inc Company Details

      • 14.2.2 Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Product and Service

    • 14.3 Shire Plc

      • 14.3.1 Shire Plc Company Details

      • 14.3.2 Shire Plc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Shire Plc Glomerulonephritis Treatment Product and Service

    • 14.4 Merck KGaA

      • 14.4.1 Merck KGaA Company Details

      • 14.4.2 Merck KGaA Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Merck KGaA Glomerulonephritis Treatment Product and Service

    • 14.5 Anthera Pharmaceuticals Inc

      • 14.5.1 Anthera Pharmaceuticals Inc Company Details

      • 14.5.2 Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Product and Service

    • 14.6 Pfizer Inc

      • 14.6.1 Pfizer Inc Company Details

      • 14.6.2 Pfizer Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Pfizer Inc Glomerulonephritis Treatment Product and Service

    • 14.7 Ra Pharmaceuticals Inc

      • 14.7.1 Ra Pharmaceuticals Inc Company Details

      • 14.7.2 Ra Pharmaceuticals Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Ra Pharmaceuticals Inc Glomerulonephritis Treatment Product and Service

    • 14.8 Retrophin Inc

      • 14.8.1 Retrophin Inc Company Details

      • 14.8.2 Retrophin Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Retrophin Inc Glomerulonephritis Treatment Product and Service

    • 14.9 Biogen Inc

      • 14.9.1 Biogen Inc Company Details

      • 14.9.2 Biogen Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Biogen Inc Glomerulonephritis Treatment Product and Service

    • 14.10 Dimerix Bioscience Pty Ltd

      • 14.10.1 Dimerix Bioscience Pty Ltd Company Details

      • 14.10.2 Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Product and Service

    • 14.11 GlaxoSmithKline Plc

      • 14.11.1 GlaxoSmithKline Plc Company Details

      • 14.11.2 GlaxoSmithKline Plc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 GlaxoSmithKline Plc Glomerulonephritis Treatment Product and Service

    • 14.12 Visterra Inc

      • 14.12.1 Visterra Inc Company Details

      • 14.12.2 Visterra Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Visterra Inc Glomerulonephritis Treatment Product and Service

    • 14.13 Rigel Pharmaceuticals Inc

      • 14.13.1 Rigel Pharmaceuticals Inc Company Details

      • 14.13.2 Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Product and Service

    • 14.14 Bristol-Myers Squibb Company

      • 14.14.1 Bristol-Myers Squibb Company Company Details

      • 14.14.2 Bristol-Myers Squibb Company Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 Bristol-Myers Squibb Company Glomerulonephritis Treatment Product and Service

    • 14.15 ChemoCentryx Inc

      • 14.15.1 ChemoCentryx Inc Company Details

      • 14.15.2 ChemoCentryx Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 ChemoCentryx Inc Glomerulonephritis Treatment Product and Service

    • 14.16 Omeros Corp

      • 14.16.1 Omeros Corp Company Details

      • 14.16.2 Omeros Corp Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.16.3 Omeros Corp Glomerulonephritis Treatment Product and Service

    • 14.17 Complexa Inc

      • 14.17.1 Complexa Inc Company Details

      • 14.17.2 Complexa Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.17.3 Complexa Inc Glomerulonephritis Treatment Product and Service

    • 14.18 Pharmalink AB

      • 14.18.1 Pharmalink AB Company Details

      • 14.18.2 Pharmalink AB Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.18.3 Pharmalink AB Glomerulonephritis Treatment Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Glomerulonephritis Treatment

    • Figure Glomerulonephritis Treatment Picture

    • Table Global Glomerulonephritis Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Glomerulonephritis Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Glomerulonephritis Treatment Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Glomerulonephritis Treatment Consumption by Country (2017-2022)

    • Figure United States Glomerulonephritis Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Glomerulonephritis Treatment Consumption and Growth Rate (2017-2022)

    • Figure China Glomerulonephritis Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Glomerulonephritis Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Glomerulonephritis Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Glomerulonephritis Treatment Consumption and Growth Rate (2017-2022)

    • Figure Global Glomerulonephritis Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Glomerulonephritis Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Glomerulonephritis Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Glomerulonephritis Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Glomerulonephritis Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Glomerulonephritis Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Glomerulonephritis Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global ACH-5228 Consumption and Growth Rate (2017-2022)

    • Figure Global AMY-101 Consumption and Growth Rate (2017-2022)

    • Figure Global Atacicept Consumption and Growth Rate (2017-2022)

    • Figure Global Avacopan Consumption and Growth Rate (2017-2022)

    • Figure Global AVX-002 Consumption and Growth Rate (2017-2022)

    • Figure Global Home Care Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global ACH-5228 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global AMY-101 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Atacicept Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Avacopan Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global AVX-002 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Home Care Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Glomerulonephritis Treatment Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Glomerulonephritis Treatment Export by Region (Top 5 Countries) (2017-2028)

    • Table Cellmid Ltd (Foundation Year, Company Profile and etc.)

    • Table Cellmid Ltd Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Cellmid Ltd Glomerulonephritis Treatment Product and Service

    • Table Achillion Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Product and Service

    • Table Shire Plc (Foundation Year, Company Profile and etc.)

    • Table Shire Plc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Shire Plc Glomerulonephritis Treatment Product and Service

    • Table Merck KGaA (Foundation Year, Company Profile and etc.)

    • Table Merck KGaA Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck KGaA Glomerulonephritis Treatment Product and Service

    • Table Anthera Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Product and Service

    • Table Pfizer Inc (Foundation Year, Company Profile and etc.)

    • Table Pfizer Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Inc Glomerulonephritis Treatment Product and Service

    • Table Ra Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Ra Pharmaceuticals Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ra Pharmaceuticals Inc Glomerulonephritis Treatment Product and Service

    • Table Retrophin Inc (Foundation Year, Company Profile and etc.)

    • Table Retrophin Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Retrophin Inc Glomerulonephritis Treatment Product and Service

    • Table Biogen Inc (Foundation Year, Company Profile and etc.)

    • Table Biogen Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biogen Inc Glomerulonephritis Treatment Product and Service

    • Table Dimerix Bioscience Pty Ltd (Foundation Year, Company Profile and etc.)

    • Table Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Product and Service

    • Table GlaxoSmithKline Plc (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline Plc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Plc Glomerulonephritis Treatment Product and Service

    • Table Visterra Inc (Foundation Year, Company Profile and etc.)

    • Table Visterra Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Visterra Inc Glomerulonephritis Treatment Product and Service

    • Table Rigel Pharmaceuticals Inc (Foundation Year, Company Profile and etc.)

    • Table Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Product and Service

    • Table Bristol-Myers Squibb Company (Foundation Year, Company Profile and etc.)

    • Table Bristol-Myers Squibb Company Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Company Glomerulonephritis Treatment Product and Service

    • Table ChemoCentryx Inc (Foundation Year, Company Profile and etc.)

    • Table ChemoCentryx Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table ChemoCentryx Inc Glomerulonephritis Treatment Product and Service

    • Table Omeros Corp (Foundation Year, Company Profile and etc.)

    • Table Omeros Corp Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Omeros Corp Glomerulonephritis Treatment Product and Service

    • Table Complexa Inc (Foundation Year, Company Profile and etc.)

    • Table Complexa Inc Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Complexa Inc Glomerulonephritis Treatment Product and Service

    • Table Pharmalink AB (Foundation Year, Company Profile and etc.)

    • Table Pharmalink AB Glomerulonephritis Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pharmalink AB Glomerulonephritis Treatment Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US